What Levolin RESPULES Treats: Main Uses and Benefits

Levolin RESPULES is commonly used when short-term symptomatic assistance is needed in situations involving distressing symptoms. This therapy is applied in clinical settings that involve acute or unstable symptom patterns associated with lung conditions like Asthma and Chronic Obstructive Pulmonary Disease (COPD).

The medication is generally used to help address symptom clusters that create noticeable physiological strain, specifically acute wheezing, pronounced shortness of breath, and uncomfortable chest tightness. The primary benefit is supportive relief during acute manifestations, which assists with easing the impact of symptoms on routine activities and supports the patient during difficult episodes by easing the overall symptom load.

Levolin RESPULES is relevant when supportive symptom management is appropriate, often used during phases when symptoms become more noticeable. It is also applied in a preemptive capacity to help prevent predictable symptoms, such as Exercise-Induced Bronchospasm (EIB). This supportive relief may assist with maintaining functional stability, which helps improve day-to-day comfort during symptomatic periods.

“This supportive relief may assist with maintaining functional stability.”

---

Quick Fact: Symptomatic Assistance This medication is primarily used to provide support during episodes of sudden symptom escalation, offering symptomatic assistance across conditions characterized by recurrent or episodic manifestations.

Regulatory References

1. NIH MedlinePlus Overview on Levalbuterol Inhalation

This section outlines the official population eligibility and exclusions for Levolin RESPULES (Levosalbutamol Inhalation Solution) as determined by governmental regulatory labeling.

Eligibility Scope

Classification	Who Can/Cannot Use
Approved Populations	Adults and adolescents, and children 6 years of age and older.
Contraindicated Populations	Individuals with a known hypersensitivity to levosalbutamol, racemic albuterol, or any other component of the product.
Pediatric Restriction	Children younger than 6 years of age are not approved for the inhalation solution, as safety and efficacy have not been formally established.

Conditional Use (Use with Caution)

The medicine must be used with caution in patients with specific pre-existing conditions:

• Cardiovascular disorders (e.g., hypertension, coronary insufficiency).
• Diabetes mellitus (due to risk of blood glucose changes).
• Hyperthyroidism (overactive thyroid).
• Convulsive disorders (seizure history).

Reproductive Status

Use during pregnancy is generally not recommended unless the potential benefit outweighs the potential risk. Caution is advised for breastfeeding women, as it is unknown if the drug is excreted into human milk. Discontinuation is required if paradoxical bronchospasm occurs after use.

Interactions with other medicines and products

The interaction profile for Levolin RESPULES, which contains the Short-Acting beta2-Agonist (SABA) levosalbutamol, is defined by restrictions on co-administration with other pharmacologically similar or antagonistic agents as documented in regulatory information. All interaction information is presented at a high, regulatory-aligned descriptive level, strictly avoiding clinical advice or therapeutic explanations.

Pharmacodynamic and Restriction-Related Interactions

Co-administration with non-selective beta-adrenergic blocking agents (Beta-Blockers) is officially restricted because these agents may block the intended bronchodilatory effects and risk inducing severe bronchospasm. Concomitant use with Monoamine Oxidase Inhibitors (MAOIs) or Tricyclic Antidepressants (TCAs) may potentiate the cardiovascular effect of levosalbutamol. Additionally, combining with other sympathomimetic aerosol bronchodilators is generally not recommended due to the potential for additive systemic effects.

Electrolyte and Drug-Exposure Interactions

Co-administration with non-potassium-sparing diuretics (such as loop or thiazide diuretics) may worsen hypokalemia or contribute to electrocardiographic changes. Regarding effects on other drugs, official documents state that co-administration may cause a decrease in serum Digoxin levels. No explicit timing-based separation rules or enzyme-mediated (CYP) interactions are mandatory in the regulatory prescribing information.

How Levolin RESPULES Works

Activating Key Airway Muscle Receptors

The drug functions as a selective agonist on beta-2 adrenergic receptors (beta2-AR), which are critical biological targets found on the smooth muscle lining the airways. Activation of these receptors initiates an internal cellular cascade that increases the production of the signaling molecule cyclic AMP (cAMP). This molecular event alters muscle activity and results in the physical dilation of the air passages.

Modulating Airway Muscle Tone and Cellular Stability

This mechanism focuses on the physiological consequence of the signaling cascade. The increased intracellular cAMP levels reduce the activity of enzymes required for muscle contraction, resulting in the relaxation of the bronchial smooth muscle and bronchodilation. This effect is a systemic physiological modulation of muscle tone. Furthermore, this mechanism extends to stabilizing specific cells (mast cells), which contributes to the modulation of mediator release from those cells.

Levolin RESPULES is a solution intended exclusively for oral inhalation via nebulization and is subject to specific instructions regarding administration and dosage. The official route requires a standard jet nebulizer connected to an air compressor for delivery. The unit-dose solution generally requires no dilution before use. Standard guidance specifies that the solution's safety has not been evaluated when it is mixed with other medications in the nebulizer.

The medicine is typically administered on a three-times-a-day (TID) schedule, maintaining intervals of 6 to 8 hours between doses. The use pattern is defined as regular administration, continued as medically indicated to manage recurring episodes. Dosage must not be exceeded.

The standard labeled dosing regimens are differentiated by age:

Population	Starting/Standard Single Dose	Maximum Routine Dose Constraint
Adults and Adolescents (ge 12 yrs)	0.63 mg per administration.	A 1.25 mg dose may be used for patients with inadequate response to the starting dose.
Children (6 to 11 yrs)	0.31 mg per administration.	Routine dosing should not exceed 0.63 mg three times a day.

Use of this inhalation solution for children under six years of age is not currently approved. If a dose is missed, standard protocols advise returning to the regular schedule without taking two doses simultaneously.

Research Evidence / Overview of Studies for Levolin RESPULES

Evidence for use in Bronchospasm Related to Asthma and COPD

Research into the active component of Levolin RESPULES, levosalbutamol, was evaluated in research involving conditions characterized by fluctuating or episodic manifestations like Asthma and Chronic Obstructive Pulmonary Disease (COPD). The initial research base includes numerous Randomized Controlled Trials (RCTs). These studies included patients presenting with stable symptoms as well as those who were experiencing acute episodes where symptoms became more noticeable. The research designs allowed investigators to compare the substance to a non-active treatment (placebo) and to the older, racemic version of the drug (salbutamol/albuterol).

These short-term studies, often lasting a few weeks to two months, monitored outcomes related to systemic or functional imbalance, specifically focusing on how much air a person could exhale in one second (FEV₁). The research also examined patient-reported experiences related to physical discomfort, such as the intensity of wheezing and shortness of breath. Evidence derived from settings with varying symptom burdens also research examined health resource use, such as the total number of breathing treatments given in a hospital setting.

---

Evidence for use in Preventing Exercise-Induced Bronchospasm (EIB)

Levosalbutamol was studied for its application in research scenarios prior to physical activity, which is relevant in trials assessing short-term or episodic symptom patterns related to exercise-induced airway changes. Studies primarily focused on outcomes related to systemic or functional imbalance by monitoring the maximum decrease in lung function after a standardized exercise challenge. Since these studies were conducted under specific, controlled conditions, the results apply only to the populations studied under those circumstances.

---

What is Still Uncertain about Levolin RESPULES

A transparent view of the research highlights areas where evidence is still developing. Research is ongoing, and certainty remains low in several areas. Long-term effects are not fully established, particularly concerning outcomes that would require many months or years of follow-up. In many initial trials, research has explored the drug in comparison to the older, racemic version. Comparative evidence is lacking regarding whether one formulation provides a definitive functional advantage over the other. The data for certain groups remain uncertain, and this evidence highlights what is known — and what is still uncertain.

Key Studies & References

1. XOPENEX (levalbuterol hydrochloride) Inhalation Solution - FDA/DailyMed Label Information
2. Efficacy and safety of nebulized levsalbutamol compared with racemic salbutamol and placebo in the treatment of asthma in pediatric patients (1999) - Pediatric RCT

Common questions about Levolin RESPULES (FAQ)

Q: How quickly do people typically notice an effect after using Levolin RESPULES?

Regulatory studies and official information indicate that the medicine is designed for rapid onset to relieve symptoms quickly. This action is characteristic of its classification as a Short-Acting beta2-Agonist, a class of medicine associated with rapid relief of airway constriction.

Q: How long is the effect of Levolin RESPULES expected to last?

The effects of the medication are generally suggested to provide symptom relief for several hours. The regular administration schedule is typically structured to maintain this therapeutic effect over the course of the day.

Q: Are there any known issues with taking Levolin RESPULES and large amounts of caffeine?

Official regulatory documents classify the active ingredient in Levolin RESPULES as a sympathomimetic agent. Combining the drug with other substances that have similar stimulating effects, including large amounts of caffeine, may potentiate the risk of side effects such as increased heart rate and blood pressure.

Q: What should people generally know about combining Levolin RESPULES with common over-the-counter cold remedies?

Co-administration with other sympathomimetic drugs, which are often found in decongestants or cold remedies, is generally not recommended. Official information indicates that this is due to the potential for additive systemic effects.

Q: Does Levolin RESPULES interact with any types of common herbal supplements?

Official documentation describes the importance of disclosing all herbal supplements and dietary supplements to a healthcare provider. This is a standard step to check for potential interactions that may affect the medicine's profile.

Q: Is a dry mouth a possible side effect of Levolin RESPULES?

Dry mouth is noted in the official regulatory documentation among the potential adverse effects reported in the clinical experience with the active ingredient.

Q: Is it possible for Levolin RESPULES to cause a cough or throat irritation?

Based on official clinical trial data and post-marketing reports, sore throat and cough are listed among the common adverse reactions.

Q: Do official documents mention any potential for Levolin RESPULES to cause muscle cramps?

Muscle cramps are listed in official documents as a possible side effect. This is sometimes associated with the drug's potential to cause a usually transient decrease in serum potassium levels (known as hypokalemia).

Q: Do studies indicate any general differences in side effect profiles between Levalbuterol and Albuterol?

Official summaries of comparative clinical trials suggest that the effects of Levalbuterol and Albuterol on heart rate and other cardiac side effects is generally similar when used at equivalent therapeutic doses. Research has explored this topic to understand if the refined formulation yields different effects.

Q: Why are some patients prescribed Levolin RESPULES instead of a standard rescue inhaler?

According to the official product information, the solution format delivered via a nebulizer is typically prescribed for specific patient needs. This format may be used for those who have difficulty coordinating the use of a standard inhaler or who require specific therapeutic dosing.

Q: Is it necessary to use the entire contents of a Levolin RESPULE once it has been opened?

The container is designed to hold a single unit dose for complete use immediately after opening, consistent with regulatory guidelines. Official information notes that the contents of the entire container are typically placed into the nebulizer cup for administration.

Levolin RESPULES (levalbuterol inhalation solution) must be stored and handled according to official regulatory specifications to maintain product stability.

Storage Requirements

• Temperature and Light: Store the product at Controlled Room Temperature, specifically between 20°C to 25°C (68°F to 77°F). It must be protected from light and excessive heat.
• Packaging Stability: The single-use vials must remain in the original protective foil pouch until use. Once the foil pouch is opened, the vials must be used within two weeks.
• Child Safety: The medication must be kept out of the sight and out of the reach of children.

---

Disposal Instructions

To dispose of unused or expired Levolin RESPULES, if a drug take-back program is unavailable, mix the medication with an undesirable substance (such as used coffee grounds) and place the mixture in a sealed container before throwing it into household trash.